Integer Holdings Corporation (NYSE: ITGR) FY Conference Summary Company Overview - Integer is a leading medical device contract development and manufacturing organization, serving large MedTech companies and emerging customers globally [2][3] - In 2025, Integer reported revenues of approximately $1.85 billion, with 60% from cardiovascular business and 36% from cardiac rhythm management [3][5] Core Business Insights - Integer operates as a one-stop shop for customers, providing a deep breadth of products and vertical integration to simplify supply chains and enhance margins [4][5] - The company has a proven track record of performance, executing a strategy over the past eight to nine years that positions it well within the MedTech ecosystem [5][6] Growth Markets and Strategies - Key growth markets include electrophysiology, structural heart, neurovascular, and neuromodulation, with a focus on building critical capabilities through dedicated growth teams [8][9] - Investments in rapid prototyping and complex manufacturing capabilities are aimed at helping customers bring products to market faster [10][11] - Integer maintains a healthy pipeline of acquisition targets to enhance capabilities and vertical integration [12] Financial Performance and Outlook - Integer has experienced a 12% CAGR from 2022 to 2025, with adjusted operating income expanding by nearly 400 basis points [24] - For 2026, the company anticipates flat to 3% organic growth, with adjusted EBITDA expected to range from -3% to +3% due to headwinds from three specific products [26][27] - The company expects to return to above-market performance in 2027, with a target of 200 basis points above market growth [25][30] Customer Relationships and Market Position - Integer works with approximately 40 emerging innovators, particularly in the neuromodulation space, with expectations of high teens CAGR growth in this segment [20][21] - The company emphasizes customer success as a key focus area, recognizing that operational excellence and leadership development are critical for long-term growth [21][22] Capital Management and M&A Strategy - Integer has a disciplined capital management approach, prioritizing organic investments and targeted tuck-in acquisitions, with a $200 million share repurchase program authorized [22][23][48] - The M&A landscape remains robust, with a strong pipeline of opportunities in the markets of interest [50][51] Key Challenges and Market Dynamics - The company faces headwinds from three products that are expected to impact performance in 2026, but these are not due to competitive losses [36][37] - The electrophysiology market is expected to grow in the mid-teens despite these challenges, supported by a strong portfolio and exposure to PFA technology [43][44] Conclusion - Integer Holdings Corporation has built a strong business with a robust pipeline and a commitment to customer success, expecting to navigate current challenges and return to above-market performance in the coming years [30][52]

Financial Data and Key Metrics Changes - For the full year 2025, sales increased by 8% on a reported basis and over 6% organically, while adjusted operating income grew by 13% [4][25] - Adjusted EPS increased by 21%, reflecting higher sales, improved profitability, and effective capital management [4][25] - In the fourth quarter, sales totaled $472 million, reflecting 5% growth on a reported basis and 2% growth on an organic basis [24] Business Line Data and Key Metrics Changes - Cardio and vascular sales increased by 11% to $284 million in Q4 2025, driven by acquisitions and strong demand in neurovascular [26] - Cardiac rhythm management and neuromodulation sales decreased by 2% to $167 million in Q4 2025, primarily due to lower demand from select emerging customers [27] Market Data and Key Metrics Changes - The medical device market remains attractive, with expected growth in mid-single digits for cardiovascular, neuromodulation, and cardiac rhythm management markets [10][11] - The company expects its underlying business to grow 4%-6% in line with the market, excluding the impact of three new products [6][35] Company Strategy and Development Direction - The company focuses on investing in differentiated capabilities and partnering with customers early in the design and development stage of new products [11][12] - A robust and diversified product development pipeline is oriented towards high-growth markets, with expectations of returning to above-market organic growth in 2027 [10][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to 200 basis points above-market organic growth in 2027, despite temporary headwinds in 2026 [7][39] - The company is maintaining a disciplined approach to capital management while investing in growth initiatives [21][39] Other Important Information - The company repurchased $50 million of common stock in Q4 2025 and announced an accelerated share repurchase program for an additional $50 million [4][5] - Adjusted effective tax rate for the full year was 17.2%, down from 18.3% in the prior year, reflecting tax benefits from R&D investment [30] Q&A Session Summary Question: Guidance on top line and the decision to lower the high end of the preliminary range - Management clarified that the adjustment was more about rounding than specific dynamics in January [42] Question: Return to operating income growth above sales growth in 2027 - Management expects margin expansion in the second half of 2026, with a return to above-market growth in 2027 [44] Question: Contribution from new products and their performance - Management indicated that the portfolio of products is expected to grow 15%-20% over the next 3-5 years, with good visibility on launch dates and expected revenues [47] Question: DSO increase and its implications - Management explained that the increase in DSO was due to limiting accounts receivable factoring to maintain financial flexibility [54] Question: Operating margin and its year-over-year decline - Management noted that fixed costs are more challenging to absorb with lower sales numbers, particularly in Q1 [60] Question: Visibility on customer forecasts and market dynamics - Management confirmed that discussions with customers align with their projections, indicating confidence in the guidance provided [66]

Financial Data and Key Metrics Changes - For the full year 2025, sales increased by 8% on a reported basis and over 6% organically, with adjusted operating income rising by 13% [4][24] - Adjusted EPS for 2025 increased by 21%, reflecting higher sales and improved profitability [4][24] - In Q4 2025, sales totaled $472 million, reflecting 5% growth on a reported basis and 2% growth organically [22] - Adjusted operating margin expanded by 74 basis points to 17.6% in Q4 2025, driven by improvements in gross margin [22][23] Business Line Data and Key Metrics Changes - Cardio and vascular sales increased by 11% to $284 million in Q4 2025, driven by acquisitions and strong demand in neurovascular [24] - Cardiac rhythm management and neuromodulation sales decreased by 2% to $167 million in Q4 2025, primarily due to lower demand from select emerging customers [25] - For the full year 2025, cardio and vascular sales increased by 17% on a trailing four-quarter basis, while CRM&N sales increased by 1% [25] Market Data and Key Metrics Changes - The medical device market remains attractive, with expected growth in mid-single digits for targeted markets such as cardiovascular and neuromodulation [10][11] - The company expects organic sales to be flat to up 3% in 2026, with a 3%-4% headwind from three new products due to lower-than-expected market adoption [5][29] Company Strategy and Development Direction - The company focuses on investing in differentiated capabilities and partnering with customers early in the design and development stages of new products [11][12] - A robust and diversified product development pipeline is oriented towards high-growth markets, with expectations of returning to above-market organic growth in 2027 [10][36] - The company maintains a disciplined approach to capital management, balancing organic investments and tuck-in acquisitions to support growth objectives [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to return to 200 basis points above-market organic growth in 2027, despite expected temporary headwinds in 2026 [6][36] - The fundamentals of the business are strong, with a focus on executing a disciplined growth strategy and continuous improvement initiatives [6][17] Other Important Information - The company repurchased $50 million of common stock in Q4 2025 and announced an accelerated share repurchase program for an additional $50 million [4][5] - Adjusted effective tax rate for the full year 2025 was 17.2%, down from 18.3% in the prior year, reflecting tax benefits from R&D investments [27] Q&A Session Summary Question: Guidance on top line and the decision to lower the high end of the preliminary range - Management clarified that the adjustment was not related to specific dynamics in January but was more about rounding [38][39] Question: Return to operating income growth above sales growth in 2027 - Management indicated that they expect margin expansion in the second half of 2026 and a return to above-market growth in 2027 [40][41] Question: Contribution from new products and their performance expectations - Management confirmed that the portfolio of products is expected to grow at a 15%-20% CAGR over the next 3-5 years, with good visibility on launch dates and expected revenues [42][45] Question: Changes in guidance and customer forecasts - Management stated that there are no specific changes to customer forecasts, and the guidance aligns with previous expectations [48][49] Question: Increase in Days Sales Outstanding (DSO) - Management explained that the increase in DSO was due to a decision to limit accounts receivable factoring in Q4 to maintain financial flexibility [50][51] Question: Operating margin and gross margin expectations - Management discussed the challenges of absorbing fixed costs in Q1 due to lower sales numbers and expected improvements in operating margin throughout the year [55][59]

Group 1 - Integer Holdings Corporation has appointed Michael Coyle to its Board of Directors, bringing over 40 years of leadership experience in the medical device industry [1][2] - Coyle's previous roles include president and CEO of iRhythm Technologies and executive vice president at Medtronic, along with leadership positions at St. Jude Medical and Eli Lilly [2] - He holds a master's degree from the Wharton School and a bachelor's degree from Case Western Reserve University, along with six U.S. patents related to cardiovascular medical devices [3] Group 2 - The Board of Integer regularly evaluates its composition to ensure it has the necessary skills and perspectives for growth [4] - Coyle's extensive experience is expected to significantly contribute to Integer's strategic initiatives and corporate culture [4] - The executive leadership team anticipates that Coyle's expertise will enhance Integer's contract development and manufacturing outsourcing strategy [4][5]